Key points are not available for this paper at this time.
Objective improvement after therapy with melphalan occurred in all patients producing only Bence Jones kappa proteins, in half of the patients with myeloma serum proteins, and in none of those producing only Bence Jones lambda proteins.
Bergsagel et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: